SCHEMBL267980

SCHEMBL267980

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2ccc(OCCOCCOC)cc2C(=O)NN=Cc2ccc(OC)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
KDM4E B2RXH2 4/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 2/20 0.48
SPHK2 Q9NRA0 3/20 0.42
SPHK1 Q9NYA1 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PKM P14618 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALOX12 P18054 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 2/20 0.41
ATM Q13315 1/20 0.40
SLC34A2 O95436 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267979 1.00 MAPT (0.48) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL268048 0.95 NPC1 (0.42) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL268047 0.95 NPC1 (0.42) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL268608 0.94 NPC1 (0.43) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL268607 0.94 NPC1 (0.43) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL268019 0.93 KDM4E (0.51) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL268018 0.93 KDM4E (0.51) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL269651 0.92 MAPT (0.40) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL269652 0.92 MAPT (0.40) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL268152 0.92 KDM4E (0.47) MAPTKDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885KDM4E 4468/4885NPC1 102/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885KDM4E 4535/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.